Combretastatin A4

Catalog No.S7783

Combretastatin A4 Chemical Structure

Molecular Weight(MW): 316.35

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 NV3oZYRKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2L1SGN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJHNMVUWOLUWgcYVt[W6xbXGgZ4VtdCCuaX7ld{whTUR3ME2zMlAxTS1yODFOwG0> MX[xPFc2OzVy
A-549 NUP1emUxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFzTOWFEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBCNTV2OTDseY5oKGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwMkDFMVA3KM7:TR?= NV3C[YJJOTh5NUO1NC=>
MCF-7 Mn2zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mmi5R5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gUWNHNTdiYoLlZZN1KGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTNwOEDFMVA3KM7:TR?= M1nONVE5PzV|NUC=
HT-29 NX\XNHpzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX3DfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDIWE0zQSClb3zvckBi\GWwb3PhdoNqdm:vYTDj[YxtKGyrbnXzMEBGTDVyPUGuNlBGNTB4IN88US=> NIPZSWgyQDd3M{Ww
MLM melanoma cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2TacWN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJG1NVSCvZXzhco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwNEDFMVA3KM7:TR?= M1LEZ|E5PzV|NUC=
M14 NF7EV3FEgXSxdH;4bYNqfHliYYPzZZk> MljjTY4hfmm2cn:gZ5l1d3SxeHnjJIFkfGm4aYT5JJdieyC2ZYP0[YQh[WejaX7zeEBpfW2jbjDt[Yxidm:vYTDjZY5k\XJiKF2xOEkh[2WubDDsbY5mNCCJSUWwQVAvODByMTFOwG0> NHnPdmoyOjd{OU[0NC=>
SK-OV3 NITFe5hEgXSxdH;4bYNqfHliYYPzZZk> M3\PemlvKH[rdILvJIN6fG:2b4jpZ{Bi[3Srdnn0fUB1\XO2ZXSgZYdicW6|dDDoeY1idiCxdnHybYFvKGOjbnPldkApW0tvT2[zLUBk\WyuIHzpcoUtKEeLNUC9NE4xODBzIN88US=> NFfLT|UyOjd{OU[0NC=>
HL60 cells MULDfZRwfG:6aXPpeJkh[XO|YYm= M4PB[FczKGh? MlTQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAxOSEQvF2= NXXHOXV1OjB5M{GzOVU>
SK-OV-3 MoTRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUS0PEBp MoHNS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2suV1ZvMzDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwNVMh|ryP NGHzZYMyQDd{MkGyOy=>
HepG2 cells NXLwU3lSS3m2b4TvfIlkcXS7IHHzd4F6 NIT3bYZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyxiSVO1NF0xNjByMEG0JO69VQ>? MXmxO|EzPzB4MR?=
ZR-75-1 MmnGR5l1d3SxeHnjbZR6KGG|c3H5 NV[4bol3S3m2b4TvfIlkcXS7IHHnZYlve3RiWmKtO|UuOSClZXzsJIxqdmVuIFnDOVA:OC5yMECyOEDPxE1? NXrjRmJnOTd{NEm2OFk>
HeLa cell NEK2RnREgXSxdH;4bYNqfHliYYPzZZk> NVLvdGFIS3m2b4TvfIlkcXS7IHHnZYlve3RiSHXMZUBk\WyuIHzpcoUtKEmFNUC9NE4xODB|IN88US=> M{jmRVE4OjR7NkS5
HCT116 cell MWnDfZRwfG:6aXPpeJkh[XO|YYm= MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBJS1RzMU[gZ4VtdCCuaX7lMEBKSzVyPUCuNFAxOzVizszN NFn3W5AyPzJ2OU[0PS=>
KBV1 cells NFH1bmVEgXSxdH;4bYNqfHliYYPzZZk> MWq3NkBp NUK3[IxCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hfmmwYnzhd5RqdmVvcnXzbZN1[W62IFvCWlEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNFQh|ryP MXuyNFc{OTN3NR?=
SKOV3 MkK3R5l1d3SxeHnjbZR6KGG|c3H5 NHW5V5FEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFA1OiEQvF2= NVzYeI9COjRyMU[wNFI>
SKOV3 cells Ml3BS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT29XOyClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUCuNFAxPDJizszN M1T1PVI{Pzd{M{C5
HeLa cells MoX6R5l1d3SxeHnjbZR6KGG|c3H5 NX7lemw2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFA2OSEQvF2= MmjwNVk5Pzl5NUi=
DU145 cells MWrDfZRwfG:6aXPpeJkh[XO|YYm= M3XOVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNFU1KM7:TR?= MX:yOFAyPjByMh?=
DU145 cells MnrMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1LFTGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9NE4xODB3NDFOwG0> MWiyN|c4OjNyOR?=
SK-N-BE MoW2VJJwdGmoZYLheIlwdiCjc4PhfS=> MorYO|IhcA>? NYC0VGlKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hW0tvTj3CSUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOVgh|ryP NXTPfZJQOjJ|Mkm1OlE>
NCIH460 cells M{XXdmN6fG:2b4jpZ4l1gSCjc4PhfS=> M3fucVQ5KGh? NEXrbGtEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0mKNE[wJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC2JO69VQ>? MUSxPFMxOzh2OR?=
KB-VIN10 cells MVLQdo9tcW[ncnH0bY9vKGG|c3H5 MlLiO|IhcA>? MkXBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNQj3WTW4yOCClZXzsd{BwfmW{LXX4dJJme3OrbnegVE1oeCBzN{CvUWRTOSCjZoTldkA4OiCqcoOgZpkhdWW2aIns[Y5mKGKudXWgZZN{[XluIFnDOVA:OC5yMEC3JO69VQ>? MlfQNlE3PDF5MEC=
HCT116 cells M4jZSWN6fG:2b4jpZ4l1gSCjc4PhfS=> Ml\EO|IhcA>? NXzKfnh[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCdM1jdeIh6dWmmaX7lJIlv[2:{cH;yZZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTB;MD6wNFA4PCEQvF2= NFHpWGczOTl3NUS1OC=>
DU145 cells NX7FU5U3S3m2b4TvfIlkcXS7IHHzd4F6 NUfTXHBnPDhiaB?= M17GN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODB6IN88US=> NI\JfpgyQDNyM{i0PS=>
RS4:11 cells MYHQdo9tcW[ncnH0bY9vKGG|c3H5 MlLqO|IhcA>? MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKVNEqxNUBk\WyuczDh[pRmeiB5MjDodpMh[nliKEOtLFQtPS2maX3leIh6dHSqaXH6c4wuOi27bDmtNkw2NWSrcHjlcpltfGW2cnH6c4xqfW1iYoLvcYll\SC2ZYP0MEBKSzVyPUCuNFAxQCEQvF2= M3i1clI2Pzh3NkC1
HCT 116 M3u4Zmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF;q[29Ed26lZX70doF1cW:wIIfobYNpKHC{b3T1Z4V{KDVyJTDpcohq[mm2aX;uJI9nKGe{b4f0bEBw\iCqdX3hckBkd2yxbjD0eY1weiCKQ2SgNVE3NCCLQ{WwQVAvODByOTFOwG0> M3\ZbVEyPzF2NkGz
HeLa cells MWDDfZRwfG:6aXPpeJkh[XO|YYm= MnfMO|IhcA>? M4PFR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJJme2G8dYLpckBj[XOnZDDmcJVwemW|Y3XuZ4Uh[XO|YYmsJGlEPTB;MD6wNFA6KM7:TR?= M4n6eVI1PjZ7OEi4
BNL 1ME A.7R.1 cells MXfDfZRwfG:6aXPpeJkh[XO|YYm= MnrjR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRm5NKDGPRTDBMldTNjFiY3XscJMtKEmFNUC9NE4xODB7IN88US=> MoXnNlU4QDV4MEW=
Calu6 M{LnOXBzd2yrZnXyZZRqd25iYYPzZZk> MlLPOFghcA>? NWSxPXduSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDZYx2PiCjZoTldkA1QCCqcoOgZpkhe3CnY4Tyc5Bpd3SxbXX0dpktKEmFNUC9NE4xODB7NDFOwG0> NVfFWnQ6OjF5N{S0PVk>
melanoma B16 cell NIT0d2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn\kR49v[2WwdILheIlwdiC5aHnjbEBxem:mdXPld{A2OCViaX7obYJqfGmxbjDv[kBoem:5dHigc4YhdXW{aX7lJI1mdGGwb33hJGIyPiClZXzsJIxqdmVuIFnDOVA:OC5yMEGg{txO MYOxNVcyPDZzMx?=
DU145 cells MWDDfZRwfG:6aXPpeJkh[XO|YYm= MnGzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? MVeyNFQ6Pjl{Mx?=
HCT116 cells M1PlSnBzd2yrZnXyZZRqd25iYYPzZZk> NVTLdIZ7PzJiaB?= NVL6RZFiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VWyCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= MlyyNlEyOTJzM{C=
HCT15 cells MXPQdo9tcW[ncnH0bY9vKGG|c3H5 NH\DRYc4OiCq M2jTV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNUDPxE1? NGjoR4UzOTFzMkGzNC=>
HL60 cells MVnQdo9tcW[ncnH0bY9vKGG|c3H5 M4G1NlczKGh? NWLVOWd6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN NF\zSI0zOTZ4M{OxPS=>
A10 cells M1nW[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3zxbFQ5KGh? MmjUS5Jwf3SqIHnubIljcXSrb36gc4YhemG2IFGxNEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? M1OwS|IzODR2MU[0
HUVEC cells NYrKfVJpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnT6OFghcA>? M1fncGdzd3e2aDDpcohq[mm2aX;uJI9nKEiXVlXDJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO Mn7ONlIxPDRzNkS=
HL60 cells NHrJeHVEgXSxdH;4bYNqfHliYYPzZZk> NYTlcnlFPzJiaB?= NEOy[21EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN NE[wd4szOjF|NkOxNi=>
HL60 cells MmLwVJJwdGmoZYLheIlwdiCjc4PhfS=> Ml\KO|IhcA>? MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MXOyNlU4QDFzMR?=
NCI-H522 cells NILSSYFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUCzelV1PDhiaB?= NInYVYRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEWyNkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? M1zkNVIzQTh{MUKy
MDA-MB-435 cells Ml3GS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX;ielN3PDhiaB?= Mk\QS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWRCNU2ELUSzOUBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? NX7LSpc2OjJ7OEKxNlI>
OVCAR3 M1v4TGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUC0PEBp NUf4PWM5T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKzJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO M2exXFIzQTh{MUKy
NCI/ADR-RES cells MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWrMRmh4PDhiaB?= MUHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? MVmyNlk5OjF{Mh?=
PC3 cells Mki4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4HqUlQ5KGh? NWTLWXN1T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN M1;PdlIzQTh{MUKy
DU145 cells NUjXWIVqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnXhOFghcA>? Ml[5S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= NELySnQzOjl6MkGyNi=>
MDA-MB-231 cells M2\CWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVi0PEBp MU\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO NVHkdI1OOjJ7OEKxNlI>
CEM cells MUfDfZRwfG:6aXPpeJkh[XO|YYm= MlnaO|IhcA>? NY\JXGFUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0WPIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN NWjaZ3VuOjJ4N{[yOFc>
HCT116 cells NGflSppEgXSxdH;4bYNqfHliYYPzZZk> NXP1e|IyPzJiaB?= MlLkR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN M1\ySFIzPjd4MkS3
MDA-MB-435 cells NXSyfnFyS3m2b4TvfIlkcXS7IHHzd4F6 MnrPO|IhcA>? NHzO[5hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MY[yNlY4PjJ2Nx?=
HaCaT cells NGDtenFRem:uaX\ldoF1cW:wIHHzd4F6 M{C4NmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHHDZXQh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> MmDoNlMxPjN2MEG=
HL60 cells MYfQdo9tcW[ncnH0bY9vKGG|c3H5 NIXCToM4OiCq M3zReWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? M3zOflI{OTF5MUex
HL60 cells MWTQdo9tcW[ncnH0bY9vKGG|c3H5 NYnjb|dWPzJiaB?= Mn7FRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSBqMz2oOEw2NWSrbXX0bJltfGirYYrvcE0zNXmuKT2yMFUu\GmyaHXufYx1\XS{YYrvcIl2dSCkcn;tbYRmKHSnc4SsJGlEPTB;MD6wNFEh|ryP MYWyOVc5PTZyNR?=
HT-29 M3f1bGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoTFS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTHQuOjliY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MorkNlU3QDlzMUG=
HL60 cells NI\2T4JRem:uaX\ldoF1cW:wIHHzd4F6 NH\vRmY4OiCq M1izemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? NHOySGwzODR{MESzPS=>
Hs578T cells NGTHVGhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVLCc5lVPDhiaB?= MoDxS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTJM2PziWIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN NVjVN3dXOjJ7OEKxNlI>
HL60 cells MoPNR5l1d3SxeHnjbZR6KGG|c3H5 NX:3fmdmPzJiaB?= NFS5N|VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN MWGyN|Q1PTR7Nh?=
SKOV3 cells MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlTOS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2tQXjNiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MVeyOVY5QTFzMR?=
MDA-MB-468 cells MoP0R5l1d3SxeHnjbZR6KGG|c3H5 M3jtZVQh\GG7cx?= M1XObGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNDDkZZl{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNVEh|ryP MX2yOFIyODVyMx?=
MCF7 cells M173PXBzd2yrZnXyZZRqd25iYYPzZZk> M1TVWFczKGh? M4DhTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJG1ETjdiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOTFzIN88US=> M3;4fVIzOzJ7NU[x
H460 NWX3ellZS3m2b4TvfIlkcXS7IHHzd4F6 NFXKNIZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPDZyIHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJidHXzeEwhUUN3ME2wMlAxOTJizszN MV6xPFc5OzJyNx?=
H460 NIfabVVRem:uaX\ldoF1cW:wIHHzd4F6 MoCyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKNE[wJINmdGy|LDDJR|UxRTBwMECxNlQh|ryP MUexOlczOjZ|Mx?=
NCI-H460 cells NHfPOodEgXSxdH;4bYNqfHliYYPzZZk> Ml\3O|IhcA>? Ml;yR5l1d3SxeHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg1PjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgeIV{fCxiSVO1NF0xNjByMUOg{txO NFfW[GEyQDN7Nki1Oy=>
OVCAR8 cells M3jlZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX:5OkBp NVSydVVRT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWK4JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKFBvZ3z5Z49xem:2ZXnuJIFnfGW{IEm2JIhzeyxiSVO1NF0xNjByMUOg{txO M{\1dVIzODR2MU[0
NCI/ADR-RES cells NXfOfZprS3m2b4TvfIlkcXS7IHHzd4F6 M2nWSmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS:DRGKtVmVUKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGK7IITyfZBidiCkbIXlJIV5[2y3c3nvckBie3OjeTygTWM2OD1yLkCwNVMh|ryP MoO4NlMzOTR2NUK=
OVCAR8 cells MorSR5l1d3SxeHnjbZR6KGG|c3H5 Mmj3PVYhcA>? MkD5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDl4IHjyd{BjgSCJaXXtd4Ehe3SjaX7pcocu[mG|ZXSgcIlocHRibXnjdo9{[2:yeTygTWM2OD1yLkCwNVMh|ryP NXXxOYhlOjVyMkW5PVE>
NCI/ADR-RES cells MYjDfZRwfG:6aXPpeJkh[XO|YYm= NXTWdotiQTZiaB?= NIjO[JBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA6PiCqcoOgZpkhT2mnbYPhJJN1[WmwaX7nMYJie2WmIHzp[4h1KG2rY4Lvd4NweHluIFnDOVA:OC5yMEGzJO69VQ>? M3S4c|I2ODJ3OUmx
OVCAR8 cells NWPPVJRMS3m2b4TvfIlkcXS7IHHzd4F6 NHvydXhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBQXkODUkigZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZpkhfHK7cHHuJIJtfWViZYjjcJV{cW:wIHHzd4F6NCCLQ{WwQVAvODBzMzFOwG0> NXq3[GZ2OjN{MUS0OVI>
HuTu 80 cells M1\ETnBzd2yrZnXyZZRqd25iYYPzZZk> MkTZO|IhcA>? NUG0bnVpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hUHWWdTC4NEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxN|ch|ryP MXiyNlMzQTV4MR?=
K562 cells MYjDfZRwfG:6aXPpeJkh[XO|YYm= M3e4dmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMtKEmFNUC9NE4xODF2IN88US=> MVqxPVg{PzV7NB?=
NCI/ADR (MDR) cells MU\GeY5kfGmxbjDhd5NigQ>? MkXTR4VtdCCleXPs[UBienKnc4SgbY4hVkOLL1HEVkApVUSUKTDj[YxteyCkeTDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTygTWM2OD1yLkCwNVUh|ryP M4nJSVE3Ozd5MUi3
HUVEC MVfQdo9tcW[ncnH0bY9vKGG|c3H5 NYfmSpFkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWXZGSyxiSVO1NF0xNjByMUWg{txO M3H6fFE3PzJ{NkOz
KB cell M1jWcnBzd2yrZnXyZZRqd25iYYPzZZk> NHTwT3RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCJINmdGxibHnu[UBjgSCvZYTofYxmdmViYnz1[UBlgWViYYPzZZktKEmFNUC9NE4xODF3IN88US=> NFfhWY4yPzB|NEG0Oy=>
KB-VIN10 cell MkLFVJJwdGmoZYLheIlwdiCjc4PhfS=> NYn6XVRxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRk1XUU5zMDDj[YxtKGyrbnWgZpkhdWW2aIns[Y5mKGKudXWg[JlmKGG|c3H5MEBKSzVyPUCuNFAyPSEQvF2= Mln5NVcxOzRzNEe=
Human SH-SY5Y neuroblastoma cells NVnmd3VUTnWwY4Tpc44h[XO|YYm= MmfwTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiSIXtZY4hW0hvU2m1XUBv\XW{b3LsZZN1d22jIHPlcIx{NCCLQ{WwQVAvODBzNTFOwG0> M4XRTFE2QTZ|N{Ky
SW620 cells M2XCdHBzd2yrZnXyZZRqd25iYYPzZZk> M3myWFczKGh? MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDTW|YzOCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyPTJizszN NWXvNHluOjJ|Mkm1OlE>
Molt4/C8 cells MnT0VJJwdGmoZYLheIlwdiCjc4PhfS=> M3[0NmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTX;seFQwSzhiY3XscJMtKEmFNUC9NE4xODF4IN88US=> MlPONVcxOzRzNUC=
ACHN cell MWHQdo9tcW[ncnH0bY9vKGG|c3H5 NVzFPFdqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBlenWpIILld4l{fGGwdDDBR2hPKGOnbHygcIlv\SCneIDy[ZN{cW6pIF3EVlEh[nliQXzhcYFzKEKudXWgZZN{[XluIFnDOVA:OC5yMEG2JO69VQ>? M3;YcVE4Ojh4M{mz
Molt4/C8 cells NYPYXZBlWHKxbHnm[ZJifGmxbjDhd5NigQ>? NXXrTIRXOyCmYYnz NIruVXVCdnSrcILvcIln\XKjdHn2[UBm\m[nY4SgZYdicW6|dDDoeY1idiCPb3z0OE9EQCClZXzsd{Bi\nSncjCzJIRigXNuIFnDOVA:OC5yMEG2JO69VQ>? M1nZfVE4PDF7NkC3

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
- Collapse

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
- Collapse
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Formulation: DMSO
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID